Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia.

TitleThree-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia.
Publication TypeJournal Article
Year of Publication2020
AuthorsKloetgen A, Thandapani P, Ntziachristos P, Ghebrechristos Y, Nomikou S, Lazaris C, Chen X, Hu H, Bakogianni S, Wang J, Fu Y, Boccalatte F, Zhong H, Paietta E, Trimarchi T, Zhu Y, Van Vlierberghe P, Inghirami GG, Lionnet T, Aifantis I, Tsirigos A
JournalNat Genet
Volume52
Issue4
Pagination388-400
Date Published2020 04
ISSN1546-1718
KeywordsAnimals, Carcinogenesis, CCCTC-Binding Factor, Cell Line, Tumor, Chromatin, Enhancer Elements, Genetic, Epigenesis, Genetic, Humans, Jurkat Cells, Mice, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Promoter Regions, Genetic, T-Lymphocytes
Abstract

Differences in three-dimensional (3D) chromatin architecture can influence the integrity of topologically associating domains (TADs) and rewire specific enhancer-promoter interactions, impacting gene expression and leading to human disease. Here we investigate the 3D chromatin architecture in T cell acute lymphoblastic leukemia (T-ALL) by using primary human leukemia specimens and examine the dynamic responses of this architecture to pharmacological agents. Systematic integration of matched in situ Hi-C, RNA-seq and CTCF ChIP-seq datasets revealed widespread differences in intra-TAD chromatin interactions and TAD boundary insulation in T-ALL. Our studies identify and focus on a TAD 'fusion' event associated with absence of CTCF-mediated insulation, enabling direct interactions between the MYC promoter and a distal super-enhancer. Moreover, our data also demonstrate that small-molecule inhibitors targeting either oncogenic signal transduction or epigenetic regulation can alter specific 3D interactions found in leukemia. Overall, our study highlights the impact, complexity and dynamic nature of 3D chromatin architecture in human acute leukemia.

DOI10.1038/s41588-020-0602-9
Alternate JournalNat Genet
PubMed ID32203470
PubMed Central IDPMC7138649
Grant ListR01 CA133379 / CA / NCI NIH HHS / United States
R01 CA194923 / CA / NCI NIH HHS / United States
R01 CA228135 / CA / NCI NIH HHS / United States
R01 CA149655 / CA / NCI NIH HHS / United States
R01 GM127538 / GM / NIGMS NIH HHS / United States
R01 CA216421 / CA / NCI NIH HHS / United States
R01 CA202025 / CA / NCI NIH HHS / United States
R00 CA188293 / CA / NCI NIH HHS / United States
UG1 CA233332 / CA / NCI NIH HHS / United States
U54 CA193419 / CA / NCI NIH HHS / United States
R35 CA220499 / CA / NCI NIH HHS / United States
P01 CA229086 / CA / NCI NIH HHS / United States
P30 CA016087 / CA / NCI NIH HHS / United States
639784 / ERC_ / European Research Council / International
Related Faculty: 
Giorgio Inghirami, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700